Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11264-11280

  Brohée, Laura ^a   Demine, Stéphane ^b   Willems, Jérome ^a   Arnould, Thierry ^b   Colige, Alain C ^a   Deroanne, Christophe F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b University of Namur   (Belgium)

Author keywords

Lipin 1; Metabolism; Prostate cancer; Rapamycin; RhoA

Indexed keywords

LIPIN 1; LIPIN 2; PHOSPHATIDIC ACID; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; REGULATOR PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; LPIN1 PROTEIN, HUMAN; LPIN2 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDATE PHOSPHATASE; PROPRANOLOL; RHOA PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIPOGENESIS; MALE; PHENOTYPE; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIPOGENESIS; MALE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PHOSPHATIDATE PHOSPHATASE; PHOSPHORYLATION; PROPRANOLOL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RHOA GTP-BINDING PROTEIN; RIBOSOMAL PROTEIN S6; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84929645865     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3595     Document Type: Article

References (58)

1. Furuta E, Okuda H, Kobayashi A and Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochimica et biophysica acta. 2010; 1805(2):141-152.
2. Baenke F, Peck B, Miess H and Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Disease models & mechanisms. 2013; 6(6):1353-1363.
3. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR. Fatty acid synthesis:a potential selective target for antineoplastic therapy. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(14):6379-6383.
4. Abramson HN. The lipogenesis pathway as a cancer target. Journal of medicinal chemistry. 2011; 54(16):5615-5638.
5. Menendez JA and Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews Cancer. 2007; 7(10):763-777.
6. Swinnen JV, Brusselmans K and Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Current opinion in clinical nutrition and metabolic care. 2006; 9(4):358-365.
7. Zaidi N, Swinnen JV and Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer research. 2012; 72(15):3709-3714.
8. Zadra G, Photopoulos C and Loda M. The fat side of prostate cancer. Biochimica et biophysica acta. 2013; 1831(10):1518-1532.
9. Flavin R, Zadra G and Loda M. Metabolic alterations and targeted therapies in prostate cancer. The Journal of pathology. 2011; 223(2):283-294.
10. Currie E, Schulze A, Zechner R, Walther TC and Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell metabolism. 2013; 18(2):153-161.
11. Smith SW, Weiss SB and Kennedy EP. The enzymatic dephosphorylation of phosphatidic acids. The Journal of biological chemistry. 1957; 228(2):915-922.
12. Harris TE and Finck BN. Dual function lipin proteins and glycerolipid metabolism. Trends in endocrinology and metabolism: TEM. 2011; 22(6):226-233.
13. Zhang P, Verity MA and Reue K. Lipin-1 Regulates Autophagy Clearance and Intersects with Statin Drug Effects in Skeletal Muscle. Cell metabolism. 2014.
14. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nature reviews Cancer. 2012; 12(6):401-410.
15. Engers R, Ziegler S, Mueller M, Walter A, Willers R and Gabbert HE. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocrine-related cancer. 2007; 14(2):245-256.
16. Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES and Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene. 2004; 23(32):5513-5522.
17. Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, Yamada T, Kamoto T, Ogawa O and Nakamura E. Activation of Rac1 is closely related to androgenindependent cell proliferation of prostate cancer cells both in vitro and in vivo. Molecular endocrinology. 2010; 24(4):722-734.
18. Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ and Wang LH. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer research. 2012; 72(12):3000-3009.
19. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279(5350):509-514.
20. Giang Ho TT, Stultiens A, Dubail J, Lapiere CM, Nusgens BV, Colige AC and Deroanne CF. RhoGDIalpha-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis. Molecular biology of the cell. 2011; 22(17):3263-3275.
21. Sembongi H, Miranda M, Han GS, Fakas S, Grimsey N, Vendrell J, Carman GM and Siniossoglou S. Distinct roles of the phosphatidate phosphatases lipin 1 and 2 during adipogenesis and lipid droplet biogenesis in 3T3-L1 cells. The Journal of biological chemistry. 2013; 288(48):34502-34513.
22. Grkovich A, Johnson CA, Buczynski MW and Dennis EA. Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. The Journal of biological chemistry. 2006; 281(44):32978-32987.
23. Albert D, Pergola C, Koeberle A, Dodt G, Steinhilber D and Werz O. The role of diacylglyceride generation by phospholipase D and phosphatidic acid phosphatase in the activation of 5-lipoxygenase in polymorphonuclear leukocytes. Journal of leukocyte biology. 2008; 83(4):1019-1027.
24. Han GS and Carman GM. Characterization of the human LPIN1-encoded phosphatidate phosphatase isoforms. The Journal of biological chemistry. 2010; 285(19):14628-14638.
25. Saci A, Cantley LC and Carpenter CL. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Molecular cell. 2011; 42(1):50-61.
26. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL and Schulze A. SREBP activity is regulated by mTORC1 and contributes to Aktdependent cell growth. Cell metabolism. 2008; 8(3):224-236.
27. Ishimoto K, Nakamura H, Tachibana K, Yamasaki D, Ota A, Hirano K, Tanaka T, Hamakubo T, Sakai J, Kodama T and Doi T. Sterol-mediated regulation of human lipin 1 gene expression in hepatoblastoma cells. The Journal of biological chemistry. 2009; 284(33):22195-22205.
28. Eaton JM, Mullins GR, Brindley DN and Harris TE. Phosphorylation of lipin 1 and charge on the phosphatidic acid head group control its phosphatidic acid phosphatase activity and membrane association. The Journal of biological chemistry. 2013; 288(14):9933-9945.
29. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate cancer and prostatic diseases. 2006; 9(3):230-234.
30. Harris TE, Huffman TA, Chi A, Shabanowitz J, Hunt DF, Kumar A and Lawrence JC, Jr. Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. The Journal of biological chemistry. 2007; 282(1):277-286.
31. Foster DA, Salloum D, Menon D and Frias MA. Phospholipase D and the Maintenance of Phosphatidic Acid Levels for Regulation of Mammalian Target of Rapamycin (mTOR). The Journal of biological chemistry. 2014; 289(33):22583-22588.
32. Fuentes L, Perez R, Nieto ML, Balsinde J and Balboa MA. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A2. The Journal of biological chemistry. 2003; 278(45):44683-44690.
33. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y and Foster DA. Phospholipase D couples survival and migration signals in stress response of human cancer cells. The Journal of biological chemistry. 2006; 281(23):15862-15868.
34. Aragones J, Jones DR, Martin S, San Juan MA, Alfranca A, Vidal F, Vara A, Merida I and Landazuri MO. Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension. The Journal of biological chemistry. 2001; 276(13):10548-10555.
35. Mylonis I, Sembongi H, Befani C, Liakos P, Siniossoglou S and Simos G. Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. Journal of cell science. 2012; 125(Pt 14):3485-3493.
36. Harma V, Knuuttila M, Virtanen J, Mirtti T, Kohonen P, Kovanen P, Happonen A, Kaewphan S, Ahonen I, Kallioniemi O, Grafstrom R, Lotjonen J and Nees M. Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene. 2012; 31(16):2075-2089.
37. Brindley DN and Pilquil C. Lipid phosphate phosphatases and signaling. Journal of lipid research. 2009; 50 Suppl:S225-230.
38. Lepley D, Paik JH, Hla T and Ferrer F. The G proteincoupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer research. 2005; 65(9):3788-3795.
39. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010; 18(1):11-22.
40. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R and Pazdur R. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. The oncologist. 2010; 15(4):428-435.
41. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A and Group R-S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372(9637):449-456.
42. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, et al. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine. 2011; 364(6):514-523.
43. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP and Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. The Journal of biological chemistry. 2012; 287(3):2090-2098.
44. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, et al. Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. The New England journal of medicine. 2012; 366(6):520-529.
45. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH and Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009; 114(14):2926-2935.
46. Mahalingam D, Medina EC, Esquivel JA, 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ and Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(1):141-153.
47. Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O and Mock BA. TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Molecular oncology. 2014; 8(2):261-272.
48. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P and Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(11):3589-3597.
49. Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA and Caplen NJ. Lossof- function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer letters. 2014; 354(2):336-347.
50. Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR and Irwin MS. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget. 2014; 5(1):161-172.
51. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M and Andre N. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents:implication in breast cancer treatment. Oncotarget. 2011; 2(10):797-809.
52. Ho TT, Merajver SD, Lapiere CM, Nusgens BV and Deroanne CF. RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha. The Journal of biological chemistry. 2008; 283(31):21588-21598.
53. Deroanne C, Vouret-Craviari V, Wang B and Pouyssegur J. EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. Journal of cell science. 2003; 116(Pt 7):1367-1376.
54. Lin Y, Schuurbiers E, Van der Veen S and De Deckere EA. Conjugated linoleic acid isomers have differential effects on triglyceride secretion in Hep G2 cells. Biochimica et biophysica acta. 2001; 1533(1):38-46.
55. Labarca C and Paigen K. A simple, rapid, and sensitive DNA assay procedure. Analytical biochemistry. 1980; 102(2):344-352.
56. Deroanne CF, Colige AC, Nusgens BV and Lapiere CM. Modulation of expression and assembly of vinculin during in vitro fibrillar collagen-induced angiogenesis and its reversal. Experimental cell research. 1996; 224(2):215-223.
57. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA and Collard JG. Rac downregulates Rho activity:reciprocal balance between both GTPases determines cellular morphology and migratory behavior. The Journal of cell biology. 1999; 147(5):1009-1022.
58. N'Diaye EN, Kajihara KK, Hsieh I, Morisaki H, Debnath J and Brown EJ. PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO reports. 2009; 10(2):173-179.